Reason for request
Inclusion on the list of medicines approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit is substantial. |
Clinical Added Value
| important |
In view of the results obtained in a population with an unfavourable prognosis and the size of the effect observed, the Transparency Committee considers that TORISEL provides a substantial improvement in actual benefit (IAB level II) compared with interferon alpha (ROFERON-A) in advanced renal cell carcinoma patients with at least 3 of the 6 prognostic risk factors. |
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
Q0ZpCSMHE2G8UDKT
